Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment

Nicole Kirchhammer; Marcel P Trefny; Priska Auf der Maur; Heinz Läubli; Alfred Zippelius

doi:10.1126/scitranslmed.abo3605

Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment

Sci Transl Med. 2022 Nov 9;14(670):eabo3605. doi: 10.1126/scitranslmed.abo3605. Epub 2022 Nov 9.

Authors

Nicole Kirchhammer¹, Marcel P Trefny¹, Priska Auf der Maur², Heinz Läubli^{3

4}, Alfred Zippelius^{1

4}

Affiliations

¹ Cancer Immunology, Department of Biomedicine, University and University Hospital Basel, Basel 4031, Switzerland.
² Tumor Heterogeneity, Metastasis and Resistance, Department of Biomedicine, University and University Hospital of Basel, Basel 4031, Switzerland.
³ Cancer Immunotherapy, Department of Biomedicine, University and University Hospital Basel, Basel 4031, Switzerland.
⁴ Medical Oncology, University Hospital Basel, Basel 4031, Switzerland.

PMID: 36350989
DOI: 10.1126/scitranslmed.abo3605

Abstract

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the tumor microenvironment. This Viewpoint aims to give an update on recent developments in immunotherapy for solid tumors and highlights progress in translational research and clinical practice.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy
Neoplasms* / pathology
Tumor Microenvironment*